332.27
Krystal Biotech Inc stock is traded at $332.27, with a volume of 167.86K.
It is up +1.20% in the last 24 hours and down -2.11% over the past month.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
See More
Previous Close:
$328.34
Open:
$333.85
24h Volume:
167.86K
Relative Volume:
0.41
Market Cap:
$9.83B
Revenue:
$417.30M
Net Income/Loss:
$225.03M
P/E Ratio:
44.41
EPS:
7.4815
Net Cash Flow:
$237.38M
1W Performance:
+1.78%
1M Performance:
-2.11%
6M Performance:
+20.19%
1Y Performance:
+121.03%
Krystal Biotech Inc Stock (KRYS) Company Profile
Name
Krystal Biotech Inc
Sector
Industry
Phone
(412) 586-5830
Address
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
KRYS
Krystal Biotech Inc
|
332.27 | 9.85B | 417.30M | 225.03M | 237.38M | 7.4815 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-27-26 | Initiated | Wolfe Research | Peer Perform |
| Jan-06-26 | Upgrade | Citigroup | Neutral → Buy |
| Mar-05-25 | Initiated | Jefferies | Buy |
| Aug-06-24 | Downgrade | Citigroup | Buy → Neutral |
| Nov-20-23 | Initiated | Goldman | Buy |
| Oct-24-23 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-12-23 | Initiated | Citigroup | Buy |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-18-23 | Initiated | Stifel | Buy |
| Feb-28-23 | Upgrade | Goldman | Neutral → Buy |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-18-22 | Initiated | BofA Securities | Buy |
| Jul-20-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-18-20 | Initiated | B. Riley FBR | Buy |
| Jun-04-20 | Initiated | Evercore ISI | Outperform |
| Sep-24-19 | Initiated | Goldman | Neutral |
| Aug-06-19 | Reiterated | H.C. Wainwright | Buy |
| Jun-24-19 | Reiterated | Chardan Capital Markets | Buy |
| Jun-24-19 | Reiterated | H.C. Wainwright | Buy |
| May-30-19 | Initiated | Guggenheim | Buy |
| Sep-11-18 | Initiated | Cantor Fitzgerald | Overweight |
View All
Krystal Biotech Inc Stock (KRYS) Latest News
Krystal Biotech(KRYS.US) Director Sells US$8.23 Million in Common Stock - Moomoo
Krystal Biotech (NASDAQ:KRYS) director Dino Rossi sells $8.2m shares - Investing.com
Dino Rossi Sells 25,000 Shares of Krystal Biotech (NASDAQ:KRYS) Stock - MarketBeat
Krystal Biotech, Inc. SEC Filing (Aug 14, 2026) - Stock Titan
KRYS Looks 0.5% Undervalued on GF Value™ - GuruFocus
Krystal Biotech Seen Positioned for Further Gains on Vyjuvek, Pipeline Readouts, RBC Says - marketscreener.com
KRYS Initiates Coverage by RBC Capital -- Rating Set to Outperfo - GuruFocus
Krystal Bio wins bullish view at RBC Capital Markets (KRYS) - Seeking Alpha
Here Are Friday’s Top Wall Street Analyst Research Calls: Cinemark, Digital Realty, Fox Corporation, Krystal Biotech, LTC Properties, Roku, Sandisk, T-Mobile US, Wayfair, and More - 24/7 Wall St.
RBC Initiates Krystal Biotech at Outperform, With $400 Price Target - marketscreener.com
Krystal Biotech (KRYS) Earnings And Pipeline Progress Put Valuation Back In Focus - Sahm
Krystal Biotech, Inc. (KRYS) Stock forecasts - Yahoo Finance UK
Wolfe Research Maintains Krystal Biotech(KRYS.US) With Hold Rating - Moomoo
Trading Systems Reacting to (KRYS) Volatility - news.stocktradersdaily.com
Bank of America Corp DE Increases Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech (KRYS) Q2 2026 Earnings Call Transcript - The Globe and Mail
If You Invested $1000 In Krystal Biotech Stock 5 Years Ago, You Would Have This Much Today - benzinga.com
Renaissance Technologies LLC Has $2.48 Million Stock Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring a 17% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Krystal Biotech (KRYS) Stock May Be Fully Valued After Its 5x Run - Yahoo Finance
Krystal Biotech Inc (KRYS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Krystal Biotech (NASDAQ:KRYS) Upgraded at Chardan Capital - MarketBeat
Krystal Biotech, Inc. (KRYS) Stock Forecasts - Yahoo Finance
California State Teachers Retirement System Has $6.76 Million Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KRYS) 2026-08-05 - Seeking Alpha
Krystal Biotech (KRYS) After Its Q2 Beat Is The Valuation Case Still Intact - Sahm
Krystal Q2 Earnings & Sales Beat Estimates, Pipeline in Focus - Yahoo Finance
Citi Maintains Krystal Biotech(KRYS.US) With Buy Rating, Raises Target Price to $386 - Moomoo
Krystal Biotech, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Brokers Issue Forecasts for Krystal Biotech FY2026 Earnings - MarketBeat
Krystal Biotech Inc at TD Cowen Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc at Bank of America Global Healthcare Conference Transcript - GuruFocus
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: VYJUVEK Sales Surge 24% as ... By GuruFocus - Investing.com Canada
Krystal Biotech Inc (KRYS) (Q2 2026) Earnings Call Highlights: V - GuruFocus
Is Krystal Biotech (KRYS) Overvalued After Q2 Earnings Beat? EPS of $1.85 & Revenue of $119.2M; GF Score: 54/100 - GuruFocus
Why Is Krystal Biotech (KRYS) Dropping 7.0%? - AlphaStreet
Krystal Biotech stock falls 7% on revenue miss despite earnings beat - Investing.com South Africa
Krystal Biotech (NASDAQ:KRYS) Shares Gap DownHere's What Happened - MarketBeat
Krystal Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Krystal Biotech Inc Earnings Call Transcript - GuruFocus
Krystal Biotech, Inc. (KRYS) Q2 Earnings and Revenues Beat Estimates - Yahoo Finance
Krystal Biotech Announces Second Quarter 2026 Financial and Operating Results - The Manila Times
Earnings Flash (KRYS) Krystal Biotech Posts Q2 EPS $1.79, vs. FactSet Est of $1.62 - marketscreener.com
Earnings Flash (KRYS) Krystal Biotech, Inc. Reports Q2 Revenue $119.2M, vs. FactSet Est of $120.9M - marketscreener.com
Krystal Biotech Reports Strong 2Q 2026 VYJUVEK Revenue Growth and Advances Multi-Program Genetic Medicines Pipeline - Quiver Quantitative
Krystal Biotech Q2 Earnings Beat Expectations - Intellectia AI
Krystal Biotech Q2 revenue rises on VYJUVEK strength - TradingView
Krystal Biotech 2Q 2026: Revenue $119.22M, EPS $1.79— 10-Q Summary - TradingView
Krystal Biotech Q2 revenue rises to $119.2 million on VYJUVEK sales - Quiver Quantitative
Krystal Biotech, Inc. (KRYS) Stock Analysis: Exploring A Promising 12.70% Upside - directorstalkinterviews.com
Healthcare of Ontario Pension Plan Trust Fund Purchases Shares of 4,664 Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech Inc Stock (KRYS) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):